Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
LLS Applauds Significant Approval for Leukemia Patients
Rye Brook, NY – June 11, 2018 – The U.S. Food and Drug Administration (FDA) decision to expand the approval of a targeted therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is a significant development in the treatment of these patients, according to The Leukemia & Lymphoma Society® (LLS). The FDA approved venetoclax (Venclexta®...
High School Students 'Test' the Limits of Philanthropy
(Rye Brook, NY, June 7, 2018) – For the second year in a row, high school students across the country are redefining what it means to be philanthropic in today’s youth culture. Through The Leukemia & Lymphoma Society’s (LLS) newest innovation in fundraising, Students of the Year, more than 600 motivated high school students raised significant funds for LLS’s cutting-edge cancer research and ...
SUBARU AND LLS CONTINUE PARTNERSHIP TO SEND HOPE, LOVE AND BLANKETS TO PATIENTS
Camden, NJ (June 1, 2018) – Everyone loves a three-peat, especially when the winning combination helps provide care and support to people fighting cancer. For the third consecutive year, Subaru of America, Inc. and The Leukemia & Lymphoma Society (LLS) will spread love, hope and warmth to cancer patients and their families in communities across the country. Over the past two years, Subaru Loves to Care, the...
LLS Response to Approval of Right to Try Legislation
Rye, Brook, NY (May 23, 2018) – The House of Representatives yesterday voted 250-169 in favor of the Right to Try Act, which the Senate passed in August 2017. The bill will now be sent to President Trump, who is expected to sign it. The Right to Try Act fails to meet all of The Leukemia & Lymphoma Society’s (LLS) principles regarding access to investigational therapies, which are outlined below....
LLS Applauds Congressional Approval of the Childhood Cancer STAR Act
Washington, D.C. (May 23, 2018) – The Leukemia & Lymphoma Society (LLS) commends the U.S. House of Representatives for unanimously approving the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act yesterday. Led by Representative Michael McCaul (R-Texas), Representative Jackie Speier (D-Calif.), Representative Mike Kelly (R-Pa.) and Representative G. K. Butterfield (D-N.C.) in the U.S. Hou...
LLS Statement on Trump Administration’s Blueprint on Drug Prices
Rye Brook, NY (May 14, 2018) – President Trump gave a speech on Friday May 11, 2018 outlining his administration’s proposal to bring down the cost of drugs. Following is a statement from The Leukemia & Lymphoma Society’s President and CEO Louis J. DeGennaro: The Leukemia and Lymphoma Society (LLS) is pleased that the Trump Administration has publicly committed to making prescription drugs more afforda...
LLS Unveils “Beating Cancer Is In Our Blood” Brand Platform
View multimedia release here. Rye Brook, N.Y. (May 7, 2018) – The Leukemia & Lymphoma Society (LLS), the largest nonprofit dedicated to fighting blood cancers, today unveiled a new brand platform showcasing its work in the fight to cure cancers. “Beating Cancer Is In Our Blood” highlights LLS’s resolve to end blood cancers, the third leading cause of cancer deaths in the U.S., and sh...
More Progress on LLS-Supported CAR T-cell Immunotherapy
Rye Brook, N.Y. (May 2, 2018) – The latest approval of a game-changing personalized cancer therapy on Tuesday is further proof of the promise of immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) supported early on and which holds great promise for blood cancer patients, as well as for patients with other types of cancers. The U.S. Food and Drug Administration (FDA) granted ti...